PTK787/ZK 222584 + paclitaxel
Phase 1Terminated 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Non-hematologic Malignancies
Conditions
Metastatic Non-hematologic Malignancies
Trial Timeline
Apr 26, 2006 → May 29, 2008
NCT ID
NCT00358163About PTK787/ZK 222584 + paclitaxel
PTK787/ZK 222584 + paclitaxel is a phase 1 stage product being developed by Novartis for Metastatic Non-hematologic Malignancies. The current trial status is terminated. This product is registered under clinical trial identifier NCT00358163. Target conditions include Metastatic Non-hematologic Malignancies.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00358163 | Phase 1 | Terminated |
Competing Products
20 competing products in Metastatic Non-hematologic Malignancies